Skip to main content
Midas Edge

ReShape Lifesciences Inc

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

HIND$1.54-3.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)** **

​​​​​​​​​​​​​​​​​​​​​​​​​​​​
​ · ​ · Series C Convertible · ​ · Series D Mirroring · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · Accumulated Other · ​ · Total
​ · ​ · Preferred Stock · ​ · Preferred Stock · ​ · Common Stock · ​ · Paid-in · ​ · Accumulated · ​ · Comprehensive · ​ · Stockholders’
​ · Shares · Amount · Shares · Amount · Shares · Amount · Capital · Deficit · Income (Loss) · Equity
Balance December 31, 2021 (As Restated)​95,388​$—​—​$—​356,641​$—​$622,399​$(577,973)​$(92)​$44,334
Net loss​—​​—​—​​—​—​​—​​—​​(46,214)​​—​​(46,214)
Other comprehensive income, net of tax​—​​—​—​​—​—​​—​​—​​—​​4​​4
Series D Mirroring preferred stock issued​—​​—​2,500​​—​—​​—​​—​​—​​—​​—
Series D Mirroring preferred stock canceled​—​​—​(2,500)​​—​—​​—​​—​​—​​—​​—
Stock-based compensation expense, net​—​​—​—​​—​—​​—​​2,087​​—​​—​​2,087
Cancellation of common stock​—​​—​—​​—​(20,045)​​—​​—​​—​​—​​—
Common stock purchased​—​​—​—​​—​47,851​​—​​639​​—​​—​​639
Issuance of stock from RSUs​—​​—​—​​—​21,362​​—​​—​​—​​—​​—
Issuance of stock for bonuses​—​​—​—​​—​28,769​​—​​318​​—​​—​​318
Institutional exercise of warrants​—​​—​—​​—​84,641​​1​​2,492​​—​​—​​2,493
Balance December 31, 2022​95,388​$—​—​$—​519,219​$1​$627,935​$(624,187)​$(88)​$3,661
Net loss​—​​—​—​​—​—​​—​​—​​(11,387)​​—​​(11,387)
Other comprehensive income, net of tax​—​​—​—​​—​—​​—​​—​​—​​—​​—
Issuance of common stock pursuant to reverse stock split​—​​—​—​​—​18,399​​—​​—​​—​​—​​—
Stock-based compensation expense, net​—​​—​—​​—​—​​—​​766​​—​​—​​766
Common stock purchased​—​​—​—​​—​3,246,395​​3​​10,137​​—​​—​​10,140
Equity issuance costs​—​​—​—​​—​—​​—​​(653)​​​​​​​​(653)
Issuance of stock from RSUs​—​​—​​​​​​2,546​​—​​—​​—​​—​​—
Institutional exercise of warrants​—​​—​—​​—​19,670,488​​19​​4,117​​—​​—​​4,136
Balance December 31, 2023​95,388​$—​—​$—​23,457,047​$23​$642,302​$(635,574)​$(88)​$6,663
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.